Search This Blog

Wednesday, July 8, 2020

Walgreens goes big into primary care

Walgreens (NASDAQ:WBA) announces that it plans to establish primary care clinics in as many as 700 U.S. stores over the “next few years.”
It will partner with VillageMD to set up the doctor-led clinics which will also include nurses, social workers and therapists.
To allow for the necessary space, it will redesign stores, including narrower shelves and less room (maybe no room) for tobacco products.
Heretofore, Walgreens has tucked tiny clinics in the back of stores where customers can get flu shots or treatment of minor ailments. Last fall, it announced that it intended to close ~40% of those.
Shares up 3% premarket on light volume.
Related tickers: (NYSE:CVS), (NYSE:RAD)
https://seekingalpha.com/news/3589429-walgreens-goes-big-primary-care

Moderna completes enrollment in mid-stage study of COVID-19 vaccine

In a post on social media, Moderna (MRNA +2.0%) announces that it has completed enrollment in a Phase 2 clinical trial evaluating the safety, reactogenicity and immunogenicity of COVID-19 vaccine candidate mRNA-1273 in 600 healthy volunteers across two age cohorts: 18-55 years old and 55+ years old.
A Phase 3 study should launch this month.
Enrollment in cohorts of older adults (56-70 years old and 71+) in an NIH-led Phase 1 trial has been completed.
Company remains on track to deliver ~500M doses/year with an upside to 1B doses/year beginning in 2021.
Selected COVID-19 vaccine players: Novavax (NVAX -1.5%), Dynavax Technologies (DVAX +6.3%), GlaxoSmithKline (GSK +0.8%), Merck (MRK +0.0%), Sanofi (SNY +0.1%), Inovio Pharmaceuticals (INO -4.0%), iBio (IBIO +5.8%), Arcturus Therapeutics (ARCT +0.4%), Soligenix (SNGX +2.0%), GeoVax Labs (OTCQB:GOVX -2.3%), Vaxart (VXRT -9.5%), Altimmune (ALT +2.9%), Vir Biotechnology (VIR +6.3%), Pfizer (PFE +0.7%), BioNTech (BNTX -2.6%), AstraZeneca (AZN +1.1%)

Japan supercomputer suggests changes to travel, work amid airborne virus threat

Supercomputer-driven models simulated in Japan suggested that operating commuter trains with windows open and limiting the number of passengers may help reduce the risk of coronavirus infections, as scientists warn of airborne spread of the virus.
In an open letter published on Monday, 239 scientists in 32 countries outlined evidence that they say shows floating virus particles can infect people who breathe them in.
The World Health Organization (WHO) acknowledged ‘evidence emerging’ of airborne transmission, but said it was not definitive.
Even if the coronavirus is airborne, questions remain about how many infections occur through that route. How concentrated the virus is in the air may also decide contagion risks, said Kyoto University professor Yuki Furuse.
In the open letter, scientists urged improvements to ventilation and the avoidance of crowded, enclosed environments, recommendations that Shin-ichi Tanabe, one of the co-authors of the letter, says Japan broadly adopted months ago.
“In Japan, the committee for COVID-19 countermeasures insisted on the 3Cs at an early stage,” said Tanabe, a professor at Waseda University in Tokyo, referring to Japan’s public campaign to avoid ‘Closed spaces, Crowded places and Close-contact settings.’ “This is ahead of the world.”
As Japan tamed the pandemic, with more than 19,000 confirmed cases and 977 deaths so far, Economy Minister Yasutoshi Nishimura credited its success to the 3Cs and its cluster-tracing strategy.
The recent study by Japanese research giant Riken using the world’s fastest supercomputer, the Fugaku, to simulate how the virus travels in the air in various environments advised several ways to lower infection risks in public settings.
Its lead researcher, Makoto Tsubokura, said that opening windows on commuter trains can increase the ventilation by two to three times, lowering the concentration of ambient microbes.
But to achieve adequate ventilation, there needs to be spaces between passengers, the simulations showed, representing a drastic change from Japan’s notoriously packed commuter trains.
Other findings advised the installation of partitions in offices and classrooms, while in hospitals, beds should be surrounded by curtains that touch the ceiling.

Panacea Biotec aims to make 1 bln doses of COVID-19 vaccine candidate in 2022

Indian biotech firm Panacea Biotec Ltd said on Wednesday it remains on schedule to produce first production quantities of COVID-19 vaccine candidate by January 2021.
Shares of Panacea Biotec rose as much as 5.9% after the news in its sharpest daily move in nearly three weeks, before trimming some gains to trade up 1.2% by 0936 GMT.
The company said last month it would partner with U.S.-based Refana Inc to make a potential COVID-19 vaccine, in a collaboration that expects to have over 40 million doses available early next year.
“We continue to evaluate candidate vaccines in pre-clinical investigations in accordance with (our) timeline. We do not envisage the commencement of clinical studies until September this year,” the company said in an emailed statement.
It has set production targets of 500 million doses for 2021 and one billion doses in 2022 for its COVID-19 vaccine candidate.
The company is looking to produce an inactivated COVID-19 vaccine, the technology for which is well known and has been used to make vaccines against diseases such as influenza and measles.
India’s Bharat Biotech and Zydus Cadila, listed as Cadila Healthcare Ltd, have received regulatory approvals to test their vaccine candidates in humans.
There are no approved vaccines for the respiratory illness caused by the new coronavirus, but 19 candidates are being trialled in humans globally. China is leading the race, with an experimental vaccine by Sinovac Biotech Ltd set to become the country’s second to enter final stage testing later this month.

FDA declines to approve Merck and Eisai’s liver cancer combo therapy

The U.S. drug regulator declined to approve a combination of Merck & Co Inc’s blockbuster cancer drug Keytruda and Eisai Co Ltd’s Lenvima as the first line of treatment in patients with liver cancer, the companies said on Wednesday.
The Food and Drug Administration’s complete response letter cited lack of sufficient evidence that the combination therapy had a meaningful advantage over available treatments for the condition, the companies said.
The companies said they plan to conduct a clinical trial to demonstrate substantial evidence of the combination’s effectiveness in liver cancer.
Merck and Eisai are continuing to evaluate Keytruda in combination with Lenvima across 13 different types of tumor in 18 trials.
The FDA letter will not impact the indications Keytruda and Lenvima are already approved for, the companies said.

CEPI to invest $66 million to boost Clover’s COVID-19 vaccine trial

China’s Clover Biopharmaceuticals Inc has received $66 million in investment from the Coalition for Epidemic Preparedness Innovation (CEPI) to bolster the testing of a potential COVID-19 vaccine, the global epidemic response group said on Wednesday.
Last month, Clover became the sixth Chinese developer of a potential COVID-19 vaccine to move into human trials by launching a study in Australia to test its vaccine with boosters.
The foundation said the funding aims to help produce hundreds of millions of doses of the potential vaccine per year and if the early stage trials are successful, it expects to provide “significant” additional support.
On successful completion of trials, the vaccine will be made available globally, it said.
CEPI’s latest investment in Clover comes on top of an initial $3.5 million in funding when they announced a partnership in April.
The Oslo, Norway-based group was set up in 2017 to fight emerging epidemics and is backed by 14 governments, the Bill and Melinda Gates Foundation and Britain’s Wellcome Trust.
CEPI has deployed vast sums of money in search of a COVID-19 vaccine through partnerships with drug developers including Inovio Pharmaceuticals Inc, Moderna Inc, and Novavax Inc.

Smiths to help make blood-based coronavirus test in Britain

Smiths Group (SMIN.L) will help produce a blood-based COVID-19 antibody test approved by Britain’s healthcare regulator in the firm’s latest involvement in tackling the coronavirus.
London-listed Smiths, whose baggage screening kit and explosive detectors are common in airports, delayed a long-sought separation of its medical unit in March to focus on making ventilators for Britain.
Smiths said on Wednesday it had agreed with privately held biopharma firm Attomarker, which makes tests for diabetes, allergies and infections, to manufacture its handheld, triple antibody COVID-19 test device for an undisclosed sum.
Antibodies are the body’s natural defence to infections, and their presence in the blood to confirm COVID-19 is also being used in tests developed by Roche (ROG.S) and Abbott (ABT.N).
Attomarker’s test for the respiratory illness caused by the coronavirus will look for three different virus proteins and three types of antibodies, improving its chances of more accurate detections even after a long period.
The firm separately said its technology, approved by Britain’s Medicines and Healthcare Products Regulatory Agency for use by the NHS, had delivered results in seven minutes with a sensitivity of up to 96%, 14 days after COVID-19 symptoms appeared in a bench-top version. (bit.ly/3iIVlAc)
Attomarker, which was spun off from the University of Exeter, focuses on making blood-testing devices that use cloud technology to connect to medical professionals.
Smiths said it had been in talks with Attomarker since April over testing and developing the technology, adding that it had the ability to scale production to meet demand.
A portable version is expected to go into production in late 2020 or early 2021.
Attomarker said that it was also testing a combined COVID-19 and flu antibody test with this year’s flu vaccine.